Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy - Full Text View

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00159679

Purpose

The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if changes in nerve function happen during the study.

Condition	Intervention	Phase
Diabetic Neuropathy, Painful	Drug: Pregabalin	Phase IV

MedlinePlus related topics: Diabetic Nerve Problems Peripheral Nerve Disorders

Drug Information available for: Pregabalin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy

Further study details as provided by Pfizer:

Primary Outcome Measures:

Nerve conduction measurements; Pain scores from patient diaries

Secondary Outcome Measures:

Proportion of patients with at least a 50% reduction in pain scores; Short-Form McGill Pain Questionnaire; Sleep interference scores from patient diaries; Clinical Global Impression of Change; Patient Global Impression of Change

Enrollment:	167
Study Start Date:	September 2004
Study Completion Date:	October 2005

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Adults with Type 1 or 2 diabetes
Patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months

Exclusion Criteria:

Patients must not be in poor or unstable health.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00159679

Show 30 Study Locations

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

Link to ClinicalStudyResults.org Posting This link exits the ClinicalTrials.gov site

No publications provided by Pfizer

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008 Sep 16;8:33.

Responsible Party:	Pfizer, Inc ( Director, Clinical Trials Disclosure Group )
Study ID Numbers:	A0081060
Study First Received:	September 8, 2005
Last Updated:	April 28, 2009
ClinicalTrials.gov Identifier:	NCT00159679 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Neuromuscular Diseases
Diabetic Neuropathies
Peripheral Nervous System Diseases
Diabetes Mellitus
Pregabalin
Endocrine System Diseases

Pain
Peripheral Nervous System Agents
Analgesics
Endocrinopathy
Anticonvulsants
Diabetes Complications

Additional relevant MeSH terms:

Diabetic Neuropathies
Nervous System Diseases
Physiological Effects of Drugs
Diabetes Mellitus
Endocrine System Diseases
Pregabalin
Pharmacologic Actions
Neuromuscular Diseases

Sensory System Agents
Therapeutic Uses
Peripheral Nervous System Diseases
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Anticonvulsants
Diabetes Complications

ClinicalTrials.gov processed this record on May 06, 2009